CDSCO bars injectable cosmetics, jolts India's $1.6B medical aesthetics market
India's drug regulator issued a public notice prohibiting injectable cosmetic products and misleading claims, putting aesthetic clinics, beauty marketers and manufacturers on notice. The crackdown covers dermal fillers, botulinum toxin and skin-brightening injectables — a category the industry pegs at $1.6 billion in 2024 and growing toward ₹13,000 crore.
CDSCO issued a public notice barring injectable cosmetic products and misleading claims, warning aesthetic clinics, beauty marketers and manufacturers. Move tightens scrutiny on India's $1.6B medical aesthetics market covering dermal fillers, botulinum toxin and skin-brightening injectables.
Why this matters
CDSCO is escalating enforcement across aesthetic categories, following its move to bar injectables from 'cosmetic' labelling and DCGI's directive that cosmetics cannot make treatment claims, squeezing clinic chains.
Retail-brand signals steady at 458 over the last 90 days.